NIKKEI 225
38,471.20 -761.60 (-1.94%) HANG SENG
16,248.97 -351.49 (-2.12%) CRUDE OIL
85.30 -0.11 (-0.13%) GOLD FUTURES
2,404.70 +21.70 (+0.91%) DOW
37,798.97 +63.86 (+0.17%) Bitcoin GBP
50,654.41 -335.39 (-0.66%)
MRNA Jun 2024 160.000 call
| Previous close | 0.4200 |
| Open | 0.3600 |
| Bid | 0.3500 |
| Ask | 0.5000 |
| Strike | 160.00 |
| Expiry date | 2024-06-21 |
| Day's range | 0.3600 - 0.5000 |
| Contract range | N/A |
| Volume | |
| Open interest | 218 |
BenzingaJohnson & Johnson Shows Focus On Strengthening Its Business Upon Its Consumer Health Unit Spinoff
On Tuesday, Johnson & Johnson (NYSE: JNJ) delivered a rather mixed first quarter report. Adjusted earnings surpassed estimates as sales in its medical devices business surged, while revenue was almost in line with estimates. First quarter results came shortly after JNJ’s expansion in the cardiovascular space with the $13.1 billion acquisition of heart device firm Shockwave Medical Inc (NASDAQ: SWAV). First Quarter Highlights For the period ended in March, the healthcare company posted a revenue
ZacksModerna, Inc. (MRNA) is Attracting Investor Attention: Here is What You Should Know
Moderna (MRNA) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Simply Wall St.Investing in Moderna (NASDAQ:MRNA) five years ago would have delivered you a 367% gain
For many, the main point of investing in the stock market is to achieve spectacular returns. While not every stock...
